8-K: Insmed's BRINSUPRI Wins Historic FDA Approval

Insmed Incorporated announced FDA approval for BRINSUPRI, the first and only treatment for non-cystic fibrosis bronchiectasis in adults and children 12 and older.

Summary

• The U.S. Food and Drug Administration (FDA) has approved BRINSUPRI (brensocatib 25 mg and 10 mg tablets), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older.
• BRINSUPRI is the first and only FDA-approved treatment for NCFB, a chronic and progressive lung disease affecting approximately 500,000 people in the U.S. and millions globally.
• The approval is based on data from the Phase 3 ASPEN and Phase 2 WILLOW studies, both published in the New England Journal of Medicine.
• In the ASPEN study, patients taking BRINSUPRI 10 mg and 25 mg experienced a 21.1% and 19.4% reduction in annual rate of exacerbations, respectively, compared to placebo.
• Both dosage strengths significantly prolonged the time to first exacerbation and increased the proportion of patients remaining exacerbation-free.
• Patients receiving BRINSUPRI 25 mg showed statistically significant less decline in lung function, as measured by forced expiratory volume in one second (FEV1), at week 52.
• BRINSUPRI is a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor, designed to inhibit the activation of enzymes in neutrophils that drive chronic airway inflammation in NCFB.
• Applications for brensocatib with the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) have been accepted, with a planned filing in Japan in 2025.
• Commercial launches are anticipated in Europe and Japan in 2026, pending approval in each territory.
• BRINSUPRI is now available in the U.S. by prescription through a comprehensive specialty pharmacy network.

Sentiment

Score: 9

Explanation: The sentiment is highly positive due to the historic FDA approval of BRINSUPRI as the first and only treatment for a significant unmet medical need (NCFB), affecting 500,000 U.S. patients. Strong clinical data, a first-in-class mechanism, and a projected peak sales estimate of over $5 billion indicate substantial commercial potential and a transformative impact on the company's outlook. While there are some adverse effects, the overall benefit and market opportunity are overwhelmingly positive.

Positives

• BRINSUPRI is the first and only FDA-approved treatment for non-cystic fibrosis bronchiectasis (NCFB), addressing a significant unmet medical need for approximately 500,000 U.S. patients.
• The drug is a first-in-class DPP1 inhibitor, targeting the underlying inflammatory process of NCFB.
• Clinical trials demonstrated a significant reduction in annual exacerbation rates (21.1% for 10 mg and 19.4% for 25 mg doses) compared to placebo.
• BRINSUPRI significantly prolonged the time to first exacerbation and increased the proportion of patients remaining exacerbation-free.
• The 25 mg dose showed a statistically significant less decline in lung function (FEV1) at week 52.
• The company projects a peak sales estimate of over $5 billion in the NCFB indication only.
• The company is well-resourced and ready for a successful launch, with a salesforce immediately engaging U.S. pulmonologists.
• Rebating strategies are expected to ensure favorable patient access.
• The approval is expected to increase NCFB diagnoses and documented pulmonary exacerbations over time, expanding the market.

Negatives

• Common adverse reactions observed in the ASPEN trial included upper respiratory tract infection, headache, rash, dry skin, hyperkeratosis, and hypertension.
• The WILLOW study showed a higher incidence of gingival and periodontal adverse reactions compared to ASPEN.
• Treatment with BRINSUPRI was associated with increases in liver function test elevations (ALT, AST, alkaline phosphatase) from baseline.
• An increased incidence of skin cancers was observed in BRINSUPRI-treated patients (0.5% for 10 mg, 1.9% for 25 mg) compared to placebo (1.1%).
• An increased incidence of alopecia was observed in BRINSUPRI-treated patients (1.5% for 10 mg, 1.6% for 25 mg) compared to placebo (0.4%).
• The use of live attenuated vaccines should be avoided in patients receiving BRINSUPRI.

Risks

• Failure to successfully commercialize BRINSUPRI in the U.S. or maintain U.S. approval.
• Failure to obtain, or delays in obtaining, regulatory approvals for BRINSUPRI in Europe or Japan.
• Regulatory approvals, if granted, may be subject to significant limitations on use or withdrawal.
• Uncertainties in the degree of market acceptance of BRINSUPRI by physicians, patients, and third-party payors.
• Inaccuracies in estimates of the size of potential markets for BRINSUPRI or data used to identify physicians.
• Uncertainties regarding expected rates of patient uptake, duration of treatment, adherence, or discontinuation rates.
• Inability to obtain adequate reimbursement from government or third-party payors or acceptable prices for BRINSUPRI.
• Development of unexpected safety or efficacy concerns related to BRINSUPRI, potentially leading to label changes, adverse sales, or market withdrawal.
• Risk that data generated in further clinical trials of brensocatib may not be consistent with the results of the ASPEN study.
• Failure to comply with agreements related to brensocatib, including the license agreement with AstraZeneca AB.
• Failure to successfully conduct future clinical trials for brensocatib, including inability to enroll or retain sufficient patients.
• Failure to obtain regulatory approval for potential future brensocatib indications.
• Failure of third parties to manufacture sufficient quantities of brensocatib for commercial or clinical needs, or to conduct clinical trials.

Future Outlook

Insmed plans to file for brensocatib approval in Japan in 2025, with commercial launches anticipated in Europe and Japan in 2026, pending regulatory approvals. The company expects BRINSUPRI's availability to increase NCFB diagnoses and documented pulmonary exacerbations over time in the U.S.

Management Comments

• "This FDA approval represents a potential paradigm shift in how we approach non-cystic fibrosis bronchiectasis... For the first time, we have a treatment that directly targets neutrophilic inflammation and addresses a root cause of bronchiectasis exacerbations. Based on the strength of the data and the impact we've seen in patients, I believe this could become the new standard in non-cystic fibrosis bronchiectasis care." Doreen Addrizzo-Harris, M.D., FCCP, Director of the NYU Langone Health Bronchiectasis and NTM Program, and ASPEN investigator.
• "The FDA approval of brensocatib represents a significant and long-awaited advancement as the first approved therapy for non-cystic fibrosis bronchiectasis. Our hope is that treatments like this will enable people with bronchiectasis to manage their condition." Elisha Malanga, Executive Director of the Bronchiectasis and NTM Association.
• "The FDA approval of the first-ever treatment for non-cystic fibrosis bronchiectasis is a historic milestone for patients and for Insmed... By keeping patients at the center of everything we do, we have once again delivered a first-in-class medicine for a disease with no prior approved treatments. This is an incredible achievement in medicine. We're deeply grateful to the patients, providers, and advocates who made this possible – this is just the beginning of what we can accomplish together for this community." Martina Flammer, M.D., MBA, Chief Medical Officer of Insmed.
• "A Historic Day for Patients with Bronchiectasis." Will Lewis, Chair & CEO of Insmed.
• "Second time launching a first-in-disease therapy for patients in the U.S." Will Lewis, Chair & CEO of Insmed.
• "Salesforce expected to begin engaging with U.S. pulmonologists about BRINSUPRI immediately." Will Lewis, Chair & CEO of Insmed.
• "We are well-resourced and ready to deliver a successful launch and transform the lives of patients with NCFB." Will Lewis, Chair & CEO of Insmed.

Industry Context

Non-cystic fibrosis bronchiectasis (NCFB) is a serious, chronic lung disease affecting approximately 500,000 people in the U.S. and millions globally, with no prior FDA-approved treatments. The approval of BRINSUPRI, a first-in-class DPP1 inhibitor, addresses a significant unmet medical need by targeting the underlying neutrophilic inflammation that drives exacerbations. This marks a potential paradigm shift in NCFB care, establishing a new standard in a previously underserved market segment within respiratory diseases.

Comparison to Industry Standards

• BRINSUPRI is the first and only FDA-approved treatment for non-cystic fibrosis bronchiectasis (NCFB), establishing a new benchmark for a disease that previously lacked targeted therapies.
• The approval is supported by robust Phase 3 (ASPEN) and Phase 2 (WILLOW) clinical trial data, both published in the New England Journal of Medicine, indicating high scientific rigor and validation comparable to leading pharmaceutical developments.
• The demonstrated 21.1% (10mg) and 19.4% (25mg) reduction in annual exacerbation rates in the ASPEN study represents a significant clinical improvement for NCFB patients, setting a new efficacy standard in this therapeutic area.
• The statistically significant less decline in lung function (FEV1) observed with the 25mg dose at week 52 provides a key differentiator in patient outcomes compared to the absence of any prior approved treatments.
• Insmed's ability to deliver a 'first-in-class' medicine for a disease with no prior approved treatments positions it as a leader in addressing rare and underserved medical conditions, similar to other biopharmaceutical companies focused on orphan or specialty indications.

Stakeholder Impact

• **Patients**: Gain access to the first and only FDA-approved treatment for NCFB, offering a new option to manage their chronic condition, potentially reducing exacerbations and lung function decline. Eligible patients may receive financial assistance and support.
• **Clinicians/Providers**: Have a new, first-in-class oral, once-daily treatment option for NCFB, which may lead to a paradigm shift in how the disease is managed.
• **Shareholders**: Likely to experience a significant positive impact due to the substantial market opportunity (projected >$5 billion peak sales), the first-in-class approval, and enhanced revenue potential.
• **Employees**: Benefit from the successful product approval and the expansion of commercialization efforts, reinforcing the company's position as a leading biopharmaceutical employer.
• **Payors**: Expected to engage in rebating to ensure favorable patient access, indicating a structured approach to market entry and reimbursement.

Next Steps

• Insmed will host a conference call on August 12, 2025, at 12:00 PM Eastern Time to discuss the FDA approval.
• The company's salesforce is expected to begin engaging with U.S. pulmonologists about BRINSUPRI immediately.
• Insmed plans to file for brensocatib approval in Japan in 2025.
• Commercial launches for BRINSUPRI are anticipated in Europe and Japan in 2026, pending regulatory approvals.
• Patients using Insmed products can enroll in the inLighten Patient Support Program for ongoing education and support.

Key Dates

Recommendation

The FDA approval of BRINSUPRI is a monumental achievement for Insmed, establishing the first and only approved treatment for non-cystic fibrosis bronchiectasis (NCFB), a condition affecting approximately 500,000 patients in the U.S. with no prior targeted therapies. The robust clinical data demonstrating significant reductions in exacerbations and improved lung function, coupled with a projected peak sales estimate exceeding $5 billion for this indication, signals a massive untapped market opportunity. The company's readiness for commercial launch and ongoing regulatory efforts in Europe and Japan further solidify its growth trajectory. This approval fundamentally transforms Insmed's market position and revenue potential, making it a compelling 'strong buy' for investors seeking exposure to a company addressing a significant unmet medical need with a first-in-class therapy.

Keywords

Biopharmaceutical, FDA approval, Non-cystic fibrosis bronchiectasis, NCFB, BRINSUPRI, brensocatib, DPP1 inhibitor, Chronic lung disease, Respiratory disease, Drug approval, Pulmonary inflammation